International prices and availability of pharmaceuticals in 2005

被引:79
作者
Danzon, Patricia M. [1 ]
Furukawa, Michael F. [2 ]
机构
[1] Univ Penn, Wharton Sch, Hlth Care Dept, Philadelphia, PA 19104 USA
[2] Arizona State Univ, Tempe, AZ USA
关键词
D O I
10.1377/hlthaff.27.1.221
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
This paper compares pharmaceutical spending, availability, use, and prices in twelve countries in 2005. Drug spending per capita was higher in the United States than in other countries. The United States had relatively high use of new drugs and high-strength formulations; other countries used more of older drugs and weaker formulations. Thus, whether U.S. overall volume of use is lower or higher depends on the measure of volume and type of product. Comprehensive price indexes show foreign prices to be 20-40 percent lower than U.S. manufacturer prices, but only 10-30 percent lower than U.S. public prices. Generics are cheaper in the United States than in other countries.
引用
收藏
页码:221 / 233
页数:13
相关论文
共 4 条
[1]   It's the prices, stupid: Why the United States is so different from other countries [J].
Anderson, GF ;
Reinhardt, UE ;
Hussey, PS ;
Petrosyan, V .
HEALTH AFFAIRS, 2003, 22 (03) :89-105
[2]   The impact of price regulation on the launch delay of new drugs - evidence from twenty-five major markets in the 1990s [J].
Danzon, PM ;
Wang, YR ;
Wang, L .
HEALTH ECONOMICS, 2005, 14 (03) :269-292
[3]  
Danzon PM, 2003, HEALTH AFFAIR, V22, pW521
[4]   Generic entry and the pricing of pharmaceuticals [J].
Frank, RG ;
Salkever, DS .
JOURNAL OF ECONOMICS & MANAGEMENT STRATEGY, 1997, 6 (01) :75-90